| BORIS/CTCFL-mediated chromatin accessibility alterations promote a pro-invasive transcriptional signature in melanoma cells. | BORIS/CTCFL-mediated chromatin accessibility alterations promote a pro-invasive transcriptional signature in melanoma cells.
Moscona R, Janssen SM, Elchebly M, Papadakis AI, Rubin E, Spatz A. | 06/1/2023 |
| Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression. | Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.
Akhtar MS, Akhter N, Talat A, Alharbi RA, Sindi AAA, Klufah F, Alyahyawi HE, Alruwetei A, Ahmad A, Zamzami MA, Deo S, Husain SA, Badi OA, Khan MJ., Free PMC Article | 05/30/2023 |
| BORIS variant SF2(C2/A4) promotes the malignant development of liver cancer by activating epithelial-mesenchymal transition and hepatic stellate cells. | BORIS variant SF2(C2/A4) promotes the malignant development of liver cancer by activating epithelial-mesenchymal transition and hepatic stellate cells.
Wei L, Liu Z, Qin L, Xian L, Chen K, Zhou S, Hu L, Xiong Y, Li B, Qin Y. | 05/15/2023 |
| Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches. | Exploring the cancer-testis antigen BORIS to design a novel multi-epitope vaccine against breast cancer based on immunoinformatics approaches.
Mahdevar E, Safavi A, Abiri A, Kefayat A, Hejazi SH, Miresmaeili SM, Iranpur Mobarakeh V. | 08/27/2022 |
| Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma. | Downregulation of BORIS/CTCFL leads to ROS-dependent cellular senescence and drug sensitivity in MYCN-amplified neuroblastoma.
Rao GK, Makani VKK, Mendonza JJ, Edathara PM, Patel N, Ramakrishna M, Cilamkoti P, Chiring Phukon J, Jose J, Bhadra U, Bhadra MP. | 05/28/2022 |
| CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy. | CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.
Salgado-Albarrán M, Späth J, González-Barrios R, Baumbach J, Soto-Reyes E., Free PMC Article | 04/2/2022 |
| Transcription Factor CTCFL Promotes Cell Proliferation, Migration, and Invasion in Gastric Cancer via Activating DPPA2. | Transcription Factor CTCFL Promotes Cell Proliferation, Migration, and Invasion in Gastric Cancer via Activating DPPA2.
Yao H, Shao Q, Shao Y., Free PMC Article | 02/5/2022 |
| CTCFL expression is associated with cerebral vascular abnormalities. | CTCFL expression is associated with cerebral vascular abnormalities.
Sati L, Soygur B, Goksu E, Bassorgun CI, McGrath J. | 01/22/2022 |
| BORIS/CTCFL expression activates the TGFbeta signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma. | BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
Makani VKK, Mendonza JJ, Edathara PM, Yerramsetty S, Pal Bhadra M. | 12/18/2021 |
| Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer. | Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer.
Miyata K, Imai Y, Hori S, Nishio M, Loo TM, Okada R, Yang L, Nakadai T, Maruyama R, Fujii R, Ueda K, Jiang L, Zheng H, Toyokuni S, Sakata T, Shirahige K, Kojima R, Nakayama M, Oshima M, Nagayama S, Seimiya H, Hirota T, Saya H, Hara E, Takahashi A., Free PMC Article | 12/18/2021 |
| CTCF and CTCFL in cancer. | CTCF and CTCFL in cancer.
Debaugny RE, Skok JA., Free PMC Article | 06/19/2021 |
| Dynamic regulation of CTCF stability and sub-nuclear localization in response to stress. | Dynamic regulation of CTCF stability and sub-nuclear localization in response to stress.
Lehman BJ, Lopez-Diaz FJ, Santisakultarm TP, Fang L, Shokhirev MN, Diffenderfer KE, Manor U, Emerson BM., Free PMC Article | 04/24/2021 |
| Defining the relative and combined contribution of CTCF and CTCFL to genomic regulation. | Defining the relative and combined contribution of CTCF and CTCFL to genomic regulation.
Nishana M, Ha C, Rodriguez-Hernaez J, Ranjbaran A, Chio E, Nora EP, Badri SB, Kloetgen A, Bruneau BG, Tsirigos A, Skok JA., Free PMC Article | 04/3/2021 |
| Data indicate that BORIS may promote cell motility and invasion in HGSC via upregulation of GALNT14. Studies provide evidence that aberrant expression of BORIS may play a role in the progression to HGSC by enhancing the migratory and invasive properties of FTSEC. | BORIS Expression in Ovarian Cancer Precursor Cells Alters the CTCF Cistrome and Enhances Invasiveness through GALNT14.
Hillman JC, Pugacheva EM, Barger CJ, Sribenja S, Rosario S, Albahrani M, Truskinovsky AM, Stablewski A, Liu S, Loukinov DI, Zentner GE, Lobanenkov VV, Karpf AR, Higgins MJ., Free PMC Article | 07/18/2020 |
| results identify a previously unrecognized role of BORIS-to promote regulatory chromatin interactions that support specific cancer phenotypes | BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
Debruyne DN, Dries R, Sengupta S, Seruggia D, Gao Y, Sharma B, Huang H, Moreau L, McLane M, Day DS, Marco E, Chen T, Gray NS, Wong KK, Orkin SH, Yuan GC, Young RA, George RE., Free PMC Article | 02/29/2020 |
| Discovering a binary CTCF code with a little help from BORIS | Discovering a binary CTCF code with a little help from BORIS.
Lobanenkov VV, Zentner GE., Free PMC Article | 09/21/2019 |
| The short rare allele of BORIS-MS2 is associated with bladder cancer risk. BORIS expression levels increase with the progression of bladder cancer. | Short rare minisatellite variant of BORIS-MS2 is related to bladder cancer susceptibility.
Kim TN, Kim WT, Jeong MS, Mun MH, Kim MH, Lee JZ, Leem SH. | 04/6/2019 |
| BORIS plays a role in epigenetic regulation of SOCS3 gene promoter methylation and histone methylation in hepatocellular carcinoma. | [BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells].
He JY, Liu QY, Wei L, Liu ZJ, Huang Y, Yu XQ, Li B, Qin Y. | 01/12/2019 |
| aberrant expression of BORIS inhibits apoptosis, promotes proliferation, and attenuates the sensitivity of colorectal cancer cells to 5-FU treatment. | Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer.
Zhang Y, Fang M, Song Y, Ren J, Fang J, Wang X., Free PMC Article | 10/20/2018 |
| These findings highlight the role of intragenic DNA methylation and DNA binding protein BORIS in cancer-specific splicing and its role in tumorigenesis. | Intragenic DNA methylation and BORIS-mediated cancer-specific splicing contribute to the Warburg effect.
Singh S, Narayanan SP, Biswas K, Gupta A, Ahuja N, Yadav S, Panday RK, Samaiya A, Sharan SK, Shukla S., Free PMC Article | 06/30/2018 |
| The CCCTC-binding factor plays critical roles in genome topology and function, increased risk of carcinogenicity, and potential of lung cancer-specific mediations. Chromosome reposition in lung cancer can be regulated by CCCTC binding factor | Tomorrow's genome medicine in lung cancer.
Wang DC, Wang X. | 12/23/2017 |
| These data provide information on the organization of the BORIS promoter region and gene regulation in normal and cancer cells. In addition, the study proposes that specific alleles of the BORIS-MS2 region could be used to identify the risk for lung cancer. | A polymorphic minisatellite region of BORIS regulates gene expression and its rare variants correlate with lung cancer susceptibility.
Yoon SL, Roh YG, Chu IS, Heo J, Kim SI, Chang H, Kang TH, Chung JW, Koh SS, Larionov V, Leem SH., Free PMC Article | 12/16/2017 |
| the results indicate that the CT antigen BORIS sf6 is specifically expressed in cervical cancer stem-like cells and cancer-initiating cells | Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.
Asano T, Hirohashi Y, Torigoe T, Mariya T, Horibe R, Kuroda T, Tabuchi Y, Saijo H, Yasuda K, Mizuuchi M, Takahashi A, Asanuma H, Hasegawa T, Saito T, Sato N., Free PMC Article | 12/9/2017 |
| BORIS is associated with the cancer stem cell-like traits of human liver cancer cells through the epigenetic regulation of OCT4. | BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q, Chen K, Liu Z, Huang Y, Zhao R, Wei L, Yu X, He J, Liu J, Qi J, Qin Y, Li B. | 09/30/2017 |
| In this study, the methylation status of BORIS was tested by methylation specific polymerase chain reaction in human hepatocarcinoma (HCC) cell lines and 43 pairs of tissue specimens. Frequently demethylation of BORIS in HCC was significantly higher than that in the paired adjacent non-tumor tissues (P=0.019), and it was correlated with tumor size (P=0.025) and clinical TNM stage (P=0.035). | Hypomethylation of BORIS is a promising prognostic biomarker in hepatocellular carcinoma.
He J, Huang Y, Liu Z, Zhao R, Liu Q, Wei L, Yu X, Li B, Qin Y. | 09/2/2017 |